Pfizer said to be adding $5B to AZ bid

Share this article:

Pfizer has sweetened the pot in its bid for AstraZeneca, Bloomberg reports. The new deal could reach $106 billion, according to a source the news service says is close to the matter.

An offer last week hovered in the $101-billion range, according to recent reports.

If the deal goes through, it would give Pfizer a lower tax rate and grant it access to a number of investigational cancer drugs.

Ian Read met with British lawmakers on April 29 to discuss the bid, according to another Bloomberg source, and the CEO “emphasized the American company's plans to carry out research, development and manufacturing in the UK, as well as the appeal of the British tax system.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.